Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Matt Mixdorf"'
Autor:
Michael P. Rettig, Samuel Achilefu, Anchal Ghai, Julie Ritchey, Alexander Zheleznyak, Matt Mixdorf, John F. DiPersio, Julie O'Neal, Monica Shokeen
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 48:1302-1311
Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying patients who
Autor:
Samuel Achilefu, Dorota Grabowska, Suman B. Mondal, Kexian Liang, Christine M. O'Brien, Gail Sudlow, Matt Mixdorf, Haini Zhang, Rui Tang, Julie L. Prior
Publikováno v:
Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XIII.
LS301 is a promising NIR fluorescence probe for targeting brain glioma cancer. The co-localization of LS31 and 5-ALA induced PpIX in vitro and in vivo enables LS301 to guide PpIX fluorescence image surgery. Moreover, LS301 showed no negative impact o
Autor:
Anchal, Ghai, Alexander, Zheleznyak, Matt, Mixdorf, Julie, O'Neal, Julie, Ritchey, Michael, Rettig, John, DiPersio, Monica, Shokeen, Samuel, Achilefu
Publikováno v:
Eur J Nucl Med Mol Imaging
PURPOSE. Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying pat